Nancy Y. Ip's research group uses genome editing technology to explore the whole brain treatment of Alzheimer's disease

In China alone, it is estimated that more than 500,000 patients suffer from hereditary AD-familial Alzheimer's disease (FAD), which is a congenital AD that is highly correlated with family history

The use of genome editing technology* as a strategy to treat diseases caused by genetic mutations (such as FAD) has great potential

Recently, a research team led by Professor Nancy Y.

At the same time, the research team also found that in the mouse model, the level of amyloid is still very low 6 months after treatment (about 1/3 of their normal lifespan), indicating this single genome editing Strategy has a lasting impact

The Morningside Professor of Life Sciences at the Hong Kong University of Science and Technology and the Director of the State Key Laboratory of Molecular Neuroscience, Professor Ye, said: “This is the first effective brain genome editing technology that can relieve the symptoms of Alzheimer’s disease in the entire brain.

This research is a joint effort of scientists from the Hong Kong University of Science and Technology, California Institute of Technology; and the Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences

*Genome editing is a technology that precisely modifies the genomic DNA of an organism by deleting, inserting, or replacing DNA at a specific location in the genome

Yangyang Duan, Tao Ye, Zhe Qu, Yuewen Chen, Abigail Miranda, Xiaopu Zhou, Ka-Chun Lok, Yu Chen, Amy KY Fu, Viviana Gradinaru, Nancy Y.